Insulin Overpricing MDL Claims
Mass Torts & Environmental Law Firm, LLC, LLC is now reviewing cases related to the Insulin Overpricing Multidistrict Litigation (MDL). If your organization is a large employer, union, government agency, school board, or university that self-funds its healthcare costs, you may be entitled to substantial compensation due to inflated insulin pricing. Call us today at (803) 247-3388 to learn more about your eligibility and take the first step toward recovering financial losses.
What Is the Insulin Overpricing MDL?
The Insulin MDL consolidates lawsuits from across the country that allege insulin manufacturers and pharmacy benefit managers (PBMs) engaged in a scheme to artificially inflate the price of insulin—causing devastating financial impacts on large organizations with self-funded healthcare plans.
The litigation centers around claims that major insulin manufacturers, including:
- Novo Nordisk
- Eli Lilly
- Sanofi
collaborated with PBMs like:
- CVS Caremark
- Express Scripts
- OptumRx
to manipulate insulin pricing through rebate-driven agreements. These agreements allowed manufacturers to keep insulin on PBM-preferred formularies while inflating list prices—leaving self-funded plans footing the bill for billions in unnecessary costs.





